

LONDON ONCOLOGY CLINICAL TRIALS

GASTRIC TUMOUR STUDIES

Disease Area	Treatment	Phase	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	Principle Investigator	Contact	Inclusion/Exclusion	
Patients referred for a GI endoscopy or underlying GI resection for cancer	Screening	NA	Observational	Non-invasive diagnostic testing for Gastro-intestinal disease	Non-invasive testing for the diagnosis and assessment of Gastro-intestinal disease	Yes	18063	Prof George Hanna	Imperial College NHS Healthcare Trust	St Mary's Hospital	Prof George Hanna	Gillian.Hornzee@imperial.nhs.uk	http://public.odp.nihr.ac.uk/QuAJAZfc/open.doc.htm?document=CRNCC_Users%2FFind%20A%20Clinical%20Research%20Study.qvw&sheet=SH75&bookmark=Document%20M02&select=LB572,-StudyID=20545	
									NHS BRENT CCG					
									NHS EALING CCG					
									NHS HAMMERSMITH AND FULHAM CCG					
									NHS HILLINGDON CCG					
Gastric Adeno carcinoma	Pre-surgical	IV	Observational	OCCAMS	Oesophageal Cancer Clinical and Molecular Stratification Study (OCCAMS) - A Multicentre Study to Determine Predictive and Prognostic Biomarkers and Therapeutic Targets for Oesophageal and Junctional Adenocarcinoma including Whole Genome Sequencing	Yes	8880	Dr Rebecca Fitzgerald	Imperial College NHS Healthcare Trust	St Mary's Hospital	Prof George Hanna	Gillian.Hornzee@imperial.nhs.uk	http://www.cancerresearchuk.org/about-cancer/trials/a-study-looking-cell-changes-pre-cancer-and-cancer-where-food-pipe-meets-stomach-occams	
									Guy's and St Thomas' NHS Foundation Trust	St Thomas' Hospital		askOHCT@gstt.nhs.uk		
									Barking, Havering and Redbridge University Hospitals NHS Trust					
									University College London Hospitals NHS Foundation Trust	University College London Hospital		CCTU.admin@uclh.nhs.uk		
	1st line	III	Interventional	Neo-AEGIS	Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (MAGIC regimen) vs. neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the oesophagus and oesophago-gastric junction.	Yes	18094	Mr Shaun Preston	Imperial College NHS Healthcare Trust	St Mary's Hospital	Prof George Hanna	Gillian.Hornzee@imperial.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT01726452	
									University College London Hospitals NHS Foundation Trust	Univeristy College London Hospital	Prof John Bridgewater	CCTU.admin@uclh.nhs.uk		
	Neoadjuvant	II	Interventional	INNOVATION TRIAL / EORTC 1203)	INtegration of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTlve stOmach caNcer	Yes	19333	Prof John Bridgewater	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Ian Chau	Ian.Chau@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02205047	
									University College London Hospitals NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	Bijal.Patel@rmh.nhs.uk		
	1st line Maintenance	III	Interventional	PLATFORM	Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial (PLATFORM Trial)	Yes	18432	Prof David Cunningham	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham			https://clinicaltrials.gov/ct2/show/NCT02678182
									Royal Free London NHS Foundation Trust	Royal Free Hospital				
Guy's and St Thomas' NHS Foundation Trust									Guy's Hospital	Dr Nick Maisey	askOHCT@gstt.nhs.uk			
Advanced 1st line	III	Interventional	G02	Alternative chemotherapy for frail or elderly patients with advanced gastric or oesophageal cancer	Yes	15037	Prof Matt Seymour	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr Nick Maisey	askOHCT@gstt.nhs.uk	https://ukctg.nihr.ac.uk/trials/trial-details/trial-details?trialNumber=ISRCTN44687907		
								Imperial College NHS Healthcare Trust	St Mary's Hospital	Dr Danielle Power	Gillian.Hornzee@imperial.nhs.uk			
								Barking, Havering and Redbridge University Hospitals NHS Trust						
								Bart's Health NHS Trust	St Bartholomew's Hospital					
	III	Interventional	GAMMA-1	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Yes	27513	Prof David Cunningham	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	David.Cunningham@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02545504		
								University College London Hospitals NHS Foundation Trust	Univeristy College London Hospital					
	III	Interventional	JAVELIN Gastric 100	A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction	No			Barts Health NHS Trust	St Bartholomew's Hospital	Dr David Propper	sue.mccartney@qmul.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02625610		
								University College London Hospitals NHS Foundation Trust	University College London Hospital	Kai-Keen Shiu	christopher.wanstall@uclh.nhs.uk			
2nd line	II	Interventional	GS-5745	A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	Yes	31219	Dr Richard Hubner	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	David.Cunningham@rmh.nhs.uk	https://clinicaltrials.gov/show/NCT02864381		
								University College London Hospitals NHS Foundation Trust	University College London Hospital		CCTU.admin@uclh.nhs.uk			
								Barts Health NHS Trust	St Bartholomew's Hospital	Prof David Propper	Hannah.Payne@bartshealth.nhs.uk Tanjil.Nawaz@bartshealth.nhs.uk			
Translational	NA	Observational	Search for a gene responsible for familial gastric cancer	Search for a gene responsible for familial gastric cancer	No		Mr Carlos Caldas	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Rosalind Eeles	Ros.Eeles@icr.ac.uk	http://www.cuh.org.uk/familial-gastric-cancer-study		
Patients on MAGIC study	Translational	NA	Observational	TransMAGIC	Translational Study for the MRC Adjuvant Gastric Cancer Infusional Chemotherapy Trial	No		Prof David Cunningham	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	David.Cunningham@rmh.nhs.uk		

LONDON ONCOLOGY CLINICAL TRIALS

GASTRIC TUMOUR STUDIES

Disease Area	Treatment	Phase	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	Principle Investigator	Contact	Inclusion/Exclusion
Her2+	1st line	II/III	Interventional	ST03	A Randomised Phase II/III trial of Peri-operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and (in selected centres) A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas.	Yes	1752	Prof David Cunningham	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr Nick Maisey	askOHCT@gstt.nhs.uk	https://clinicaltrials.gov/ct2/show/study/NCT00450203
									Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	David.Cunningham@rmh.nhs.uk	
									Royal Free London NHS Foundation Trust	Royal Free Hospital			
									Bart's Health NHS Trust	St Bartholemew's Hospital	Dr Sarah Slater		
								Barking, Havering and Redbridge University Hospitals NHS Trust	Queen's Hospital	Dr Sherif Raouf			
c-MYC and HER2 amplified	2nd line+	II	Interventional	iMYC	Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma (iMYC)	No		Dr Ian Chau	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Ian Chau	yemong.to@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/study/NCT02884453
FGFR1/2 Amplified Gastric, oesophageal, breast or SCC of lung cancer	Advanced	II	Interventional	Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours	Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours	No		Prof David Cunningham	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	angela.gillbanks@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/study/NCT01795768?term=azd4547&rank=7
GIST - 6-20 years	2nd line+	I/II	Interventional	A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor	A Phase I/II Study Of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor	No		Dr Robin Jones	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Robin Jones	Robin.Jones@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/study/NCT01396148
metastatic GIST	1st line	II	Interventional	ALT GIST	A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)	No		Dr Charlotte Benson	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Charlotte Benson	Charlotte.Benson@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/study/NCT02365441
GIST	Adjuvant	III	Interventional		Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study	No		Dr Robin Jones	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Robin Jones	Robin.Jones@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/study/NCT02413736
	Advanced	Ib/2	Interventional		A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumours	No		Dr Ian Chau	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Ian Chau	Ian.Chau@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/study/NCT02599324
	Advanced	I	Interventional	CANC - 4893	A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Yes	19678	Dr Robin Jones	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Robin Jones	Robin.Jones@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/study/NCT02508532
Any solid tumours	Advanced	Ib	Interventional	CANC 5088	A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	No		Dr. Juanita S Lopez	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Dr. Juanita S Lopez	mahesha.ganegoda@icr.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT02722954
		I	Interventional	CANC 5659 (REFMAL 444)	A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4Antibody) in Subjects with Advanced Solid Tumors	No			Barts Health NHS Trust	St Bartholomew's Hospital			
									University College London Hospitals NHS Foundation Trust	University College London Hospital	Dr Rebecca Kristeleit	r.kristeleit@ucl.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT02261220
									Royal Free London NHS Foundation Trust	Royal Free Hospital			
									Sarah Cannon Research Institute UK			SCRI Referral Template	
Patients with anaemia undergoing major open abdominal surgery	Supportive Care	III	Interventional	PREVENTT	A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose with placebo in patients with anaemia undergoing major open abdominal surgery	Yes	13680	Dr Toby Richards	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Dr Ravishankar Raobaikady	Ravishankar.Raobaikady@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/study/NCT01692418
									Hillingdon Hospitals NHS Foundation Trust	Hillingdon Hospital	Dr Cheryl Messer		
									Bart's Health NHS Trust	Royal London Hospital	Dr Shubha Allard	Shubha.Allard@bartshealth.nhs.uk	
									Royal Free London NHS Foundation Trust	Royal Free Hospital	Dr Susan Mallett		
									King's College Hospital	King's College Hospital	Dr Tim Hughes		
									University College London Hospitals NHS Foundation Trust	University College London Hospital	Dr Khaled Dawas	CCTU.admin@uclh.nhs.uk	
									Imperial College Healthcare NHS Trust	St Mary's Hospital	Dr Asela Dharmadasa	Gillian.Hornzee@imperial.nhs.uk	
									Imperial College Healthcare NHS Trust	Charing Cross Hospital	Dr Asela Dharmadasa	susan.mcinerney@imperial.nhs.uk	
Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr Jugdeep Dhesei	askOHCT@gstt.nhs.uk										
All cancers receiving chemo	Delivery of treatment	III	Interventional	Cancer And Venous Access (CAVA)	Cancer and Venous Access (CAVA) - A randomised controlled trial with associated qualitative research of venous access devices for the delivery of long-term chemotherapy	Yes	14600	Prof Jon Moss	Imperial College Healthcare NHS Trust	Hammersmith Hospital	Dr Alison Graham	Hammersmith.Cancertrials@imperial.nhs.uk	http://www.isrctn.com/ISRCTN44504648